

## Gene Section

### Mini Review

# CDKN2a (cyclin dependent kinase 2a) / p16

Raphael Saffroy, Antoinette Lemoine, Brigitte Debuire

Service de Biochimie et Biologie moléculaire, Hôpital Universitaire Paul Brousse, 14 avenue Paul Vaillant Couturier, 94800 Villejuif, France (RS, AL, BD)

Published in Atlas Database: August 2004

Online updated version : <http://AtlasGeneticsOncology.org/Genes/CDKN2aID146.html>

DOI: 10.4267/2042/38121

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2004 Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Identity

**Other names:** p16; INK4; p16- INK4a; TP16; CDK4I; MTS1

**HGNC (Hugo):** CDKN2A

**Location:** 9p21.3

### DNA/RNA

#### Description

The gene encompasses 6.6 kb of DNA; 3 exons.

#### Transcription

471 nucleotides mRNA. The CDKN2 gene generates several transcript variants from different promoters. Each transcript differs in its first exon (E1), and utilizes alternate polyadenylation sites. E1-alpha, which is spliced into the common exons E2 and E3, gives rise to the p16-INK4 transcript.

### Protein

#### Description

156 amino acids; 16.5 kDa protein.

#### Expression

Moderately expressed in many organs as thymus, liver, pancreas, prostate, lung, or kidney.

#### Function

P16-INK4a interacts strongly with cyclin-dependent kinases 4 and 6 and inhibits their ability to interact with cyclins D. P16-INK4a induces cell cycle arrest at G1 and G2/M checkpoints, blocking them from phosphorylating RB1 and preventing exit from G1 phase of the cell cycle. P16-INK4a could act as a negative regulator of the proliferation of normal cells.

### Homology

Belongs to the cdkn2 cyclin-dependent kinase inhibitor family.

### Implicated in

#### *Cutaneous malignant melanoma 2 (CMM2)*

##### Disease

Malignant melanoma arises de novo or from a preexisting benign nevus, which occurs most often in the skin but also may involve other sites.

##### Oncogenesis

Familial melanoma (comprising between 8 and 12% of all melanoma cases) is a genodermatosis transmitted as an autosomal dominant trait. CDKN2a has been identified as a major susceptibility gene for melanoma. However this gene accounts for a minority of familial melanoma. P16 is functionally inactivated by mutations or deletions, however, because many such mutations occur in exon 2, they can potentially also affect the alternative reading frame (ARF) protein.

#### *Familial atypical multiple mole melanoma carcinoma syndrome (FAMMM)*

##### Disease

Patients with the FAMMM syndrome are genetically loaded with an increased risk of developing melanoma and other malignant neoplasms, for example, a pancreatic cancer.

##### Oncogenesis

FAMMM syndrome is an autosomal dominant disorder with variable incomplete penetrance of the clinical phenotypes. Germline mutations in the p16-INK4a

gene were found in approximately 40% of the FAMMM syndrome.

### **Sporadic cancer**

#### **Disease**

Defects in CDKN2a are involved in tumor formation in a wide range of tissues.

#### **Prognosis**

Aberrant p16 expression is associated with more aggressive behavior.

#### **Oncogenesis**

LOH on 9p21 is one of the most frequent genetic alterations identified in human cancer. However, point mutations of p16 on the other chromosome are relatively rare. Promoter methylation appears as the commonest mechanism of p16 gene inactivation.

## References

- Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. *J Natl Cancer Inst.* 1988 Sep 21;80(14):1159-64
- Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature.* 1993 Dec 16;366(6456):704-7
- Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. *Nat Genet.* 1994 Sep;8(1):15-21
- Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavitigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. *Science.* 1994 Apr 15;264(5157):436-40
- Bartsch D, Shevlin DW, Tung WS, Kisker O, Wells SA Jr, Goodfellow PJ. Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. *Genes Chromosomes Cancer.* 1995 Nov;14(3):189-95
- Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. *Nat Genet.* 1995 Oct;11(2):210-2
- Koh J, Enders GH, Dynlacht BD, Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. *Nature.* 1995 Jun 8;375(6531):506-10
- Little M, Wainwright B. Methylation and p16: suppressing the suppressor. *Nat Med.* 1995 Jul;1(7):633-4
- Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med.* 1995 Jul;1(7):686-92
- Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell.* 1995 Dec 15;83(6):993-1000
- Stone S, Jiang P, Dayananth P, Tavitigian SV, Katcher H, Parry D, Peters G, Kamb A. Complex structure and regulation of the P16 (MTS1) locus. *Cancer Res.* 1995 Jul 15;55(14):2988-94
- Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. *Cell.* 1996 Apr 5;85(1):27-37
- Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. *Mol Med.* 1997 Jan;3(1):5-20
- Quelle DE, Cheng M, Ashmun RA, Sherr CJ. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF. *Proc Natl Acad Sci U S A.* 1997 Jan 21;94(2):669-73
- Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. *Nature.* 2001 Sep 6;413(6851):83-6
- Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. *Nature.* 2001 Sep 6;413(6851):86-91
- Sharpless E, Chin L. The INK4a/ARF locus and melanoma. *Oncogene.* 2003 May 19;22(20):3092-8
- Czajkowski R, Placek W, Drewa G, Czajkowska A, Uchańska G. FAMMM syndrome: pathogenesis and management. *Dermatol Surg.* 2004 Feb;30(2 Pt 2):291-6

---

*This article should be referenced as such:*

Saffroy R, Lemoine A, Debuire B. CDKN2a (cyclin dependent kinase 2a) / p16. *Atlas Genet Cytogenet Oncol Haematol.* 2004; 8(4):287-288.

---